secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001437749-25-009859
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing
--------------------------------------------------------------------------------

- Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).
- Cash $5.5M at Dec 31, 2024, down from $6.5M; R&D expense $23.7M (up from $20.7M) on trial manufacturing.
- BARDA $400M award supports 10,000-patient Phase 2b trial of GEO-CM04S1; manufacturing and sites confirmed.
- DSMB cleared experimental arm of Phase 2 CLL trial after mRNA control arm failed primary endpoint.
- Phase 2 booster data for GEO-CM04S1 in healthy adults expected H1 2025; GEO-MVA clinical eval expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/0001437749-25-009859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/govx20250327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer